A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Fluconazole; Itraconazole; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 09 Mar 2017 Status changed to active, no longer recruiting.
- 03 Jan 2017 Status changed from active, no longer recruiting to completed.
- 12 Dec 2016 Planned End Date changed from 1 May 2016 to 1 Nov 2017.